Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Sep;38(9):889-894.
doi: 10.15537/smj.2017.9.19349.

Efficacy and adverse events of pirfenidone in treating idiopathic pulmonary fibrosis

Hui Ren  1 , Kai Wang, Hao Yang, Lingyun Gao
Affiliations
Review

Efficacy and adverse events of pirfenidone in treating idiopathic pulmonary fibrosis

Hui Ren et al. Saudi Med J. 2017 Sep.

Abstract

To analyze the efficacy and adverse events (AEs) of pirfenidone in idiopathic pulmonary fibrosis (IPF) trials. Methods: MEDLINE, Cochrane Library, and ClinicalTrials.gov were searched for studies published before June 2016. All studies of clinical trials with the key words IPF or idiopathic pulmonary fibrosis or lung fibrosis and pirfenidone or Esbriet were identified. Quality assessment and data extraction nwere conducted by 2 independent researchers. A meta-analysis of randomized controlled trials (RCTs) was performed, and relative risk (RR) and 95% confidence intervals (95% CIs) were calculated. Results: Five studies were included in this review, involving 1568 participants. The meta-analysis revealed that pirfenidone reduced the risk of decline in forced vital capacity (FVC)% ≥10% from baseline (relative risk: 0.62; 95% CI: 0.51-0.76, p less than 0.001). The pirfenidone group had a significantly higher rate of AEs compared with the placebo group. Pirfenidone did not reduce mortality from any cause significantly (odds ratio: 0.63; 95% CI: 0.36-1.09). Conclusions: This study showed that pirfenidone could reduce disease progression as assessed by the decline in FVC in IPF. Pirfenidone represents a suitable treatment option for patients with IPF.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Literature search and selection, RCT - randomized controlled trials, IPF - idiopathic pulmonary fibrosis
Figure 2
Figure 2
Forest plot showing comparison of the effect of pirfenidone versus placebo on change in forced vital capacity% ≥10%,
Figure 3
Figure 3
Forest plot showing comparison of the effect of pirfenidone versus placebo on change in progression-free survival
Figure 4
Figure 4
Forest plot showing comparison of the effect of pirfenidone versus placebo on mortality from any cause and mortality related to Idiopathic pulmonary fibrosis
Figure 5
Figure 5
Forest plot showing comparison of the effect of pirfenidone versus placebo on the change in the incidence of adverse events.
See this image and copyright information in PMC

References

    1. Israël-Biet D, Juvin K, Dang Tran K, Badia A, Cazes A, Delclaux C. Idiopathic pulmonary fibrosis: diagnosis and treatment in 2013. Rev PneumolClin. 2014;70:108–117. French. - PubMed
    1. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183:788–824. - PMC - PubMed
    1. Raghu G, Weycker D, Edelsberg J, Bradford WZ, Oster G. Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2006;174:810–816. - PubMed
    1. King TE, Jr, Pardo A, Selman M. Idiopathic pulmonary fibrosis. Lancet. 2011;378:1949–1961. - PubMed
    1. Azuma A, Nukiwa T, Tsuboi E, Suga M, Abe S, Nakata K, et al. Double-blind, placebo-controlled trial of pirfenidone in patientswith idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2005;171:1040–1047. - PubMed

MeSH terms